Jonakayem Pharma Formulation (OPC) Pvt. Ltd.


Send Inquiry
Formulary: Generic Formulary
Category: Endocrine System
International Brand Name: Dexacort
Dosages: 0.5 MG/4 MG/ML
Unit of Packing: Tablets
In treatment of: Antiemetic

Adverse Effects: 

  • Susceptibility to infection
  • Peptic ulcer
  • Haemorrhage
  • Glycosuria
  • Hyperglycaemia
  • Osteoporosis
  • Atrophy of adrenal cortex(on prolonged therapy)
  • Suppression of adrenocorticotropic hormone
  • Cushing`s syndrome
  • Inhibition of growth in children
  • Amenorrhoea
  • Behavioral disturbances
  • Thromoembolic disorders
  • Myopahy
  • Weaknss
  • Lymphocytopenia
  • Muscle wasting
  • Gastrointestinal discomfort
  • Increased appetite
  • Delayed wound healing
  • Headache
  • Euphoria
  • Insomnia
  • Seizures
  • Heart failure
  • Arrhythmias
  • Posterior sub capsular cataract
  • Glaucoma
  • Hirsutism
  • Increased intracranial pressure Eye preparation:
  • Burning
  • Redness
  • Stinging in the eye
  • Blurred vision


  • Hypersensitivity to the drug
  • Psychosis
  • Tuberculosis
  • Untreated infections
  • Systemic fungal infections
  • Osteoporosis
  • Congestive heart failure
  • Renal impairment

Special Precaution: 

  • Avoid sudden discontinuation of the drug
  • Use lower dosages as much as possible
  • Ocular herpes simplex
  • Primary glaucoma
  • Peptic ulcer
  • Epilepsy
  • Recent myocardial infarction
  • Heart failure
  • Diabetes mellitus
  • Hypothyroidism
  • Cirrhosis
  • Stress
  • Sepsis
  • Hypertension
  • Myasthenia gravis
  • Hepatic impairment
  • Non specific Ulcerative colitis
  • Diverticulitis
  • Recent intestinal anastomosis
  • Thromboembolic disorders Eye preparation:
  • Cataracts
  • Contact lens wearer
  • Diabetes
  • Glaucoma

Interaction: ENDOCRINE SYSTEM: Barbiturates: Decreases efficacy of dexamethasone. Carbamazepine, Primidone: Decreases efficacy. Oral contraceptives: Increases efficacy of dexamethasone. Ephedrine: Decrease efficacy of dexamethasone. Oestrogens: Decrease efficacy of dexamethasone Hydantoins: Decrease efficacy of dexamethasone Ketoconazole: Increase efficacy of dexamethasone Rifampicin: Decreases efficacy. Dexamethasone effects the actions of the following: Anticholinesterases: Efficacy antagonised in myasthenia gravis. Oral anticoagulants: Altered response. Cyclosporine: Increased cyclosporine efficacy leading to enhanced toxicity. Digitalis glycosides: Increased toxicity associated with hypokalaemia. Isoniazid: Decreased serum levels of isoniazid. Salicylates: Decreased serum levels of salicylates. Diuretics: Increase efficacy may cause increased hypokalaemia and increased hyperglycemia. Non-depolarising muscle relaxants: Altered response. Theophyllines: Altered response of either agent. IUCDs: contraceptive failure. Lab. Tests: a) Increases serum cholesterol levels. Increases urine glucose levels. Decreases Thyroid I131 uptake. Decreases T3 serum levels. Decreases serum potassium. Brain Scan: Dexamethasone alters result of brain scan due to decreased uptake of radioactive material.

 Servings: Oral: 0.5 to 10mg/day depending up on the severity of the condition. I.M. or I.V.: 0.5 to 20mg/day I.M. or as slow I.V. injection depending up on the severity of the condition; repeated as required up to 80mg/day. Antiemetic: 4 to 8 mg by mouth immediately before moderately-emetogenic chemotherapy and 20 mg by intravenous injection for more severely emetogenic chemotherapy. Children: 100mcg to 500mcg/kg/day